172703-35-4

Upstream product

• 97545-57-8 (E)-heptadec-2-en-1-ol 
• 172703-33-2 Toluene-4-sulfonic acid (2S,3S)-((3E,7E)-3-docosa-3,7-dienyl)-oxiranylmethyl ester 
• 172703-31-0 (2E,6E,10E)-9-Phenylsulfanyl-pentacosa-2,6,10-trien-1-ol 
• 172703-52-5 [(2S,3S)-((3E,7E)-3-Docosa-3,7-dienyl)-oxiranyl]-methanol 
• 172703-32-1 (2E,6E,10E)-Pentacosa-2,6,10-trien-1-ol 
• 172703-30-9 [((E)-Heptadec-2-enyl)sulfanyl]-benzene 
• 172703-47-8 (E)-Henicos-6-en-2-ynoic acid ethyl ester 
• 172703-50-3 (2E,6E)-Henicosa-2,6-dien-1-ol 
• 172703-48-9 (2E,6E)-1-Bromo-henicosa-2,6-diene 
• 172703-46-7 (E)-Icos-5-en-1-yne 
• 172703-45-6 (E)-1-Bromo-heptadec-2-ene 
• 98-59-9 p-toluenesulfonyl chloride 
• 2833-98-9 heptadec-2-yl-1-ol 
• 112-71-0 1-Bromotetradecane 

Downstream Products

• 172703-53-6 Toluene-4-sulfonic acid (S)-2-{(2R,5R)-5-[(R)-3-((4R,5R)-2,2-dimethyl-5-tetradecyl-[1,3]dioxolan-4-yl)-1-hydroxy-propyl]-tetrahydro-furan-2-yl}-2-hydroxy-ethyl ester 

Relevant academic research and scientific papers

Total synthesis of (+)-13,14-threo-densicomacin

The title compound was synthesized from propargyl alcohol and L-glutamic acid via a convergent approach using Sharpless asymmetric epoxidation and asymmetric dihydroxylation for the introduction of chiral centers and Pd0-catalyzed coupling for construction of the carbon skeleton.